TICKERNERD
Menu
CELCCELCHealthcare · Biotechnology

CELC Stock Forecast: Celcuity, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$83
−2.39% on the day

The 12 Wall Street analysts covering Celcuity, Inc. hold a median 12-month price target of $163 — +95.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.1B
Ticker Nerd rank
27 / 100
Median analyst target
$163
Analysts covering
12
Revenue$0.0
Operating income−$66.1M
Net income−$78.9M
Free cash flow−$55.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.5%
1M
−5.3%
YTD
−16.3%
1Y
+45.3%
From 52W high
−42.4%
From 52W low
+84.5%
$45
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CELC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celcuity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
87
Momentum
69
Quality
54
Volatility
45
Accruals
38
Growth
31
Revisions
30
Size
26
Issuance
6

Value (87): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CELC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26CELCHigh $177Median $163Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $140Median $163High $177

The green dot is the last close — the median target sits +95.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
17 Aug 2026CitizensReiteratesMarket Outperform$177
17 Aug 2026GuggenheimMaintainsBuy$165 → $175
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$155
14 Aug 2026NeedhamMaintainsBuy$157 → $140
14 Aug 2026StifelMaintainsBuy$175 → $150
15 July 2026CitizensMaintainsMarket Outperform$160 → $177
15 July 2026CitizensMaintainsMarket Outperform—
15 July 2026HC Wainwright & Co.MaintainsBuy—
15 July 2026HC Wainwright & Co.MaintainsBuy$145 → $155
3 June 2026Craig-HallumMaintainsBuy—
3 June 2026Craig-HallumMaintainsBuy$189 → $171
3 June 2026HC Wainwright & Co.MaintainsBuy$185 → $145
3 June 2026HC Wainwright & Co.MaintainsBuy—
3 June 2026Wells FargoMaintainsOverweight—
3 June 2026Wells FargoMaintainsOverweight$183 → $166
18 May 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026NeedhamReiteratesBuy—
15 May 2026Wells FargoMaintainsOverweight—
4 May 2026CitizensMaintainsMarket Outperform—
4 May 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CELC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Celcuity, Inc. returned +45.3% against +17.5% for the S&P 500, dividends included.

CELC vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26CELCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Celcuity, Inc. (CELC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−22.0×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
−357.9×

Cheaper than 99% of US stocks

EV / EBITDA
−19.6×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1433.7%

Higher than 1% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Celcuity, Inc. (CELC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celcuity, Inc. has a market value of $4.1B and an enterprise value of $4.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$226.5M.

  • Diluted earnings per share, trailing twelve months: $−4.30.

  • Free cash flow in the twelve months to 30 June 2026: −$192.3M, after $271K of capital spending.

  • Shares outstanding: 48.9M.

  • Trailing P/E: −22.0×; forward P/E: −1043.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Celcuity, Inc. employs 155 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

CELC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELCCelcuity, Inc.$4.1B
27
MANEVeradermics, Inc.$4.1B
2
RLAYRelay Therapeutics, Inc.$4.0B
71
ELVNEnliven Therapeutics, Inc.$3.9B
68
TNGXTango Therapeutics, Inc.$3.9B
41
IOVAIovance Biotherapeutics, Inc.$3.8B
90
PBLSParabilis Medicines, Inc.$4.4B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celcuity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CELC news & analysis

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Seeking Alpha · 9 Sept 2026neutral

Celcuity Inc. presented prepared remarks at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation made available via Seeking Alpha. The item documents the company's participation and remarks at the industry conference.

Why it matters — The presentation offers CELC watchers insight into the company's latest corporate messaging and positioning as delivered to an investment community audience.

Celcuity To Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Celcuity announced that its CEO and Co-founder Brian Sullivan will present and be available for one-on-one investor meetings at upcoming investor conferences, as disclosed on September 1, 2026.

Why it matters — CELC watchers would care because the CEO's participation at investor conferences offers additional opportunities for the company to communicate its pipeline and strategy to the investment community.

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

GlobeNewsWire · 26 Aug 2026positive

Celcuity announced it has submitted a supplemental New Drug Application to the FDA for REVTORPYK (gedatolisib), intended for patients with HR+, HER2- locally advanced or metastatic breast cancer carrying a PIK3CA mutation who have progressed on or after at least one line of endocrine therapy.

Why it matters — This submission advances a key regulatory milestone for Celcuity's lead candidate gedatolisib in a specific breast cancer patient population.

Celcuity: REVTORPYK Is Now A Commercial Story

Seeking Alpha · 14 Aug 2026positive

Celcuity received FDA approval for REVTORPYK (gedatolisib) with rapid NCCN Category 1 inclusion, and VIKTORIA-1 data showing improved efficacy and tolerability. Its financials reflect front-loaded commercial investment with rising SG&A, while a strengthened $754M cash position provides funding visibility into 2029.

Why it matters — A CELC watcher would care because the FDA approval and NCCN Category 1 inclusion de-risk the drug's clinical and commercial adoption, positioning REVTORPYK as a potential blockbuster franchise.

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Benzinga · 14 Aug 2026neutral

Celcuity reported a second-quarter loss that was narrower than expected on Thursday. In response, analysts have cut their forecasts for the company.

Why it matters — Celcuity watchers would care because analysts revising their projections directly affects expectations for the company's financial outlook.

FAQ

Frequently asked questions about CELC stock

What is the CELC stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Celcuity, Inc. have a median 12-month price target of $163, with estimates ranging from $140 to $177. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELC stock a buy right now?

Of the 12 analysts covering Celcuity, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celcuity, Inc. 27 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELC?

As at 12 Sept 2026, Celcuity, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (87 of 100).

Will CELC stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +95.3% from the last close, and Ticker Nerd's factor model ranks Celcuity, Inc. 27 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELC stock forecast for 2030?

No analyst covering Celcuity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $177 over the next 12 months.

How has CELC stock performed over the past year?

Celcuity, Inc. returned +45.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celcuity, Inc. do?

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications.

What is the latest news on CELC?

The most recent item we track (Seeking Alpha, 9 Sept 2026): "Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript". Celcuity Inc. presented prepared remarks at Citigroup's Biopharma Back to School Summit 2026, with a transcript of the presentation made available via Seeking Alpha. The item documents the company's participation and remarks at the industry conference.

Company

About Celcuity, Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s current work centers on cancer treatments that act on the PAM pathway, including its lead therapeutic candidate gedatolisib, which is being developed for advanced breast cancer and metastatic castration-resistant prostate cancer. Celcuity also operates a cellular analysis platform used to identify abnormal signaling activity in tumors and help guide the development of precision oncology therapies. Its business is concentrated in oncology drug development, with programs aimed at patients whose cancers are driven by specific molecular pathways. Headquartered in Minneapolis, Minnesota, Celcuity is positioned as a research-driven biotech company working across therapeutic development and biomarker-based cancer analysis.

CEO Mr. Brian F. Sullivan · 155 employees · United States · https://www.celcuity.com